Sunday , December 17 2017
Home / Resources / Clinical Presentations / Improving Outcomes with SGLT-2 Inhibitors in Challenging T2DM Patients, Part 2

Improving Outcomes with SGLT-2 Inhibitors in Challenging T2DM Patients, Part 2

In this second set of a comprehensive four-part series of Homerun Slides on SGLT-2 inhibitors, we review some of the data of the second and third approved SGLT-2 inhibitors in the U.S., dapagliflozin (Farxiga) and empagliflozin (Jardiance), along with the Durability and Limitations of this drug class….

To download this set of Homerun Slides in PowerPoint format (.ppt), just use this link: Improving Outcomes with SGLT-2 Inhibitors in Challenging T2DM Patients, Part 2

Other sets in this series (.ppt) format:

Improving Outcomes with SGLT-2 Inhibitors in Challenging T2DM Patients, Part 1
Improving Outcomes with SGLT-2 Inhibitors in Challenging T2DM Patients, Part 3

Improving Outcomes with SGLT-2 Inhibitors in Challenging T2DM Patients, Part 4

To download the entire series (74 slides) in PDF format, just use this link: Improving Outcomes with SGLT2 Inhibitors in Challenging T2DM Patients

See more SGLT-2 Resources